CompanyGraph
Grifols, S.A.
GRF · BME · Spain
Price data from its 0RDU listing on LSE
grifols.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleLevered free cash flow is -$224.46M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 1.1: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
6.26BEUR7.23B · vs all stocks (USD)
Trailing P/E
55.66xRevenue (TTM)
6.48BEUR7.48B · vs all stocks (USD)
Profit Margin
0.13%Beta
0.5034xvs all stocks
52-Week Change
-24.84%vs all stocks
Market Capitalization
6.26BEUR7.23B · vs all stocks (USD)
Enterprise Value
18.93BEUR21.85B · vs all stocks (USD)
Trailing P/E
55.66xPEG Ratio
9.56xPrice to Sales (TTM)
0.9771xPrice to Book (MRQ)
1.03xEnterprise to Revenue
2.92xEnterprise to EBITDA
20.55xGross Margin
36.47%Profit Margin
0.13%Operating Margin
9.47%Return on Assets (TTM)
1.80%Return on Equity (TTM)
1.24%Revenue (TTM)
6.48BEUR7.48B · vs all stocks (USD)
Revenue per Share (TTM)
9.40EURUpdated Jul 14, 2026Quarterly Revenue Growth
7.80%Gross Profit (TTM)
2.33BEUR2.69B · vs all stocks (USD)
EBITDA (TTM)
1.53BEUR1.77B · vs all stocks (USD)
Net Income (TTM)
8.41MEUR9.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-42.40%Operating Cash Flow (TTM)
-146.13MEUR-168.68M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-194.46MEUR-224.46M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
2.33BEURFY2025 · Dec 31, 2025Revenue
7.52BEURFY2025 · Dec 31, 2025Cost of Goods Sold
4.67BEURFY2025 · Dec 31, 2025Gross Profit
2.86BEURFY2025 · Dec 31, 2025Operating Income
1.25BEUR1.44B · vs all stocks (USD)
Pre-tax Income
615.00MEURFY2025 · Dec 31, 2025Income Tax Expense
115.00MEURFY2025 · Dec 31, 2025Net Income
500.00MEURFY2025 · Dec 31, 2025EBIT
1.19BEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.66BEURFY2025 · Dec 31, 2025Research & Development
426.00MEURFY2025 · Dec 31, 2025Selling, General & Administrative
1.06BEURFY2025 · Dec 31, 2025Other Operating Expenses
-1.00MEURFY2025 · Dec 31, 2025Non-operating Interest Income
34.00MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
576.00MEURFY2025 · Dec 31, 2025EPS (Basic)
0.5900EURFY2025 · Dec 31, 2025EPS (Diluted)
0.5900EURFY2025 · Dec 31, 2025Basic Shares Outstanding
680.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
680.51MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-98.00MEURFY2025 · Dec 31, 2025Operating Cash Flow
1.58BEURFY2025 · Dec 31, 2025Free Cash Flow
1.32BEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
825.00MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
615.00MEURFY2025 · Dec 31, 2025Depreciation & Amortization
450.00MEURFY2025 · Dec 31, 2025Other Non-cash Items
645.00MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-32.00MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-93.00MEURFY2025 · Dec 31, 2025Capital Expenditures
-261.00MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-158.00MEURFY2025 · Dec 31, 2025Net Acquisitions
-108.00MEURFY2025 · Dec 31, 2025Purchase of Investments
-57.00MEURFY2025 · Dec 31, 2025Sale of Investments
5.00MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-421.00MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-119.00MEURFY2025 · Dec 31, 2025Common Dividends Paid
-128.00MEURFY2025 · Dec 31, 2025Other Financing Charges
-282.00MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-529.00MEURFY2025 · Dec 31, 2025Shares Outstanding
680.58MSharesUpdated Jul 14, 2026Float Shares
545.93MSharesUpdated Jul 14, 2026% Held by Insiders
30.57%vs all stocks
% Held by Institutions
30.20%vs all stocks
Total Cash (MRQ)
541.10MEUR624.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7970EURUpdated Jul 14, 2026Total Debt (MRQ)
10.03BEUR11.58B · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.22xCurrent Ratio (MRQ)
2.56xBook Value per Share (MRQ)
8.64EURUpdated Jul 14, 2026Total Assets
19.71BEUR22.75B · vs all stocks (USD)
Total Current Assets
5.07BEURFY2025 · Dec 31, 2025Total Liabilities
12.11BEURFY2025 · Dec 31, 2025Total Non-current Assets
14.64BEURFY2025 · Dec 31, 2025Total Non-current Liabilities
10.09BEURFY2025 · Dec 31, 2025Total Current Liabilities
2.02BEURFY2025 · Dec 31, 2025Cash
793.00MEURFY2025 · Dec 31, 2025Cash Equivalents
8.00MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
801.00MEURFY2025 · Dec 31, 2025Other Short-term Investments
23.00MEURFY2025 · Dec 31, 2025Accounts Receivable
651.00MEURFY2025 · Dec 31, 2025Inventory
3.30BEURFY2025 · Dec 31, 2025Accounts Payable
841.00MEURFY2025 · Dec 31, 2025Short-term Debt
523.00MEURFY2025 · Dec 31, 2025Deferred Revenue
34.00MEURFY2025 · Dec 31, 2025Other Current Liabilities
80.00MEURFY2025 · Dec 31, 2025Long-term Debt
9.04BEURFY2025 · Dec 31, 2025Other Non-current Liabilities
50.00MEURFY2025 · Dec 31, 2025Common Stock (Book)
120.00MEURFY2025 · Dec 31, 2025Retained Earnings
300.00MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
7.60BEUR8.78B · vs all stocks (USD)
Treasury Stock
131.00MEURFY2025 · Dec 31, 202552-Week Low
8.45EURUpdated Jul 14, 202652-Week High
13.70EURUpdated Jul 14, 202652-Week Change
-24.84%vs all stocks
Beta
0.5034xvs all stocks
50-Day MA
9.10EURUpdated Jul 14, 2026200-Day MA
10.15EURUpdated Jul 14, 2026Avg 10-Day Volume
30.56KSharesUpdated Jul 14, 2026Avg 30-Day Volume
17.38KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
0.1600EURUpdated Jul 14, 2026Other Income / Expense
-31.00MEURFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Rising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Operating income rose four years, with small depreciation on a capital-heavy balance sheet.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 9,706,424.61Operating Cash Flow (USD, TTM): -168,679,851.336
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.56Altman Z-Score: 1.10
Financial Health
Altman Z-Score 1.1: distress zoneCritical
Altman Z-Score: 1.10
High earnings qualityNotable
Earnings Quality Score: 1.89
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Levered free cash flow is -$224.46M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -224,463,233.4Global P5: -219,013,500
Market cap is $7.23B, above the global median of $1.15BNotable
Market cap (USD): 7,229,236,647.846Global Median: 1,146,734,693.424
Revenue is $7.48B, above the global median of $520.53MNotable
Revenue (USD): 7,478,438,135.107Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Liquidia Corporation
Tier 1ProductionApproval-Gated PipelineRule
Biocon Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lantheus Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
H. Lundbeck A/S
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthRising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Chipotle Mexican Grill, Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthRising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Novartis AG
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthRising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet